A phase II study to investigate the efficacy of cyclophosphamide as sole graft-versus-host-prophylaxis after allogeneic stem cell transplantation (OCTET-CY)
Read time: 1 mins
Last updated:3rd Jan 2011
To assess the efficacy of post-transplantation cyclophosphamide as single-agent GvHD prophylaxis after allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma or lymphoma and to describe the influence of the modified immunosuppression concept on relapse rates, minimal residual disease, immune reconstitution and chimerism.
|Study start date||2011-01-03|